 |
|
|
Table 2. Platinums and Platinum-based Drug Combinations Studied in Second-line Randomized Trials
| Drug regimen |
Comparator |
Comments |
| Cisplatin + doxorubicin + cyclophosphamide |
Paclitaxel
|
Combination superior survival and PFS.[4] |
| Carboplatin + epirubicin |
Carboplatin
|
No difference in PFS and OS.[5] |
| Carboplatin + gemcitabine
|
Carboplatin
|
Combination superior PFS; not powered to determine OS differences.[6] |
| Cisplatin or carboplatin + paclitaxel |
Single platinums or nontaxane combinations
|
Combination with paclitaxel superior in PFS, OS. See text above.[3] |
References
-
Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375): 2099-106, 2003.
[PUBMED Abstract]
-
Cantù MG, Buda A, Parma G, et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (5): 1232-7, 2002.
[PUBMED Abstract]
-
Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81 (1): 3-9, 2001.
[PUBMED Abstract]
-
Pfisterer J, Vergote I, Du Bois A, et al.: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1): 36-41, 2005 May-Jun.
[PUBMED Abstract]
|
|
|
